Dr Lal PathLabs Soars 8% on Q1FY27 Earnings Beat; Nomura and Nuvama Maintain Buy

The Quick Take

• Dr Lal PathLabs shares surged 8% after Q1FY27 earnings beat analyst estimates on higher realisations
• Nomura and Nuvama maintained Buy ratings; brokerages cited pricing power and volume recovery
• Revenue growth driven by international expansion and premium test mix shift

Dr Lal PathLabs (NSE: LALPATHLAB) delivered a standout first quarter for FY27, with earnings per share exceeding consensus estimates. The diagnostics major reported higher average realisations per test — a key profitability metric — even as total test volumes showed measured growth. Management attributed the improvement to a product mix shift toward premium and specialised panels, which carry higher ticket sizes and wider margins than routine blood work.

Brokerages responded quickly: Nomura reiterated its Buy recommendation while raising its target price, pointing to structural demand for quality diagnostics in Tier-1 cities and the company's network advantage. Nuvama similarly kept its positive stance, noting that Dr Lal's capital-light franchise model limits downside risk in a competitive sector. Both houses flagged international expansion — particularly in the Gulf and Southeast Asia — as a medium-term growth driver that the market had not yet fully priced in.

The 8% single-session rally pushed the stock toward the upper band of its six-month trading range, prompting technical traders to watch the ₹3,200–₹3,400 resistance zone. For fundamental investors, the Q1 print matters because it confirms that post-COVID diagnostics spending has re-normalised at a higher baseline. With hospital capex plans accelerating across India, third-party diagnostic labs that can integrate with hospital pathways stand to capture incremental referral volumes through FY27 and FY28.

Synthesized from 1 source.